Discussion
For the first time, a person with Duchenne muscular dystrophy (DMD) has been given an experimental gene-editing therapy, called PBGENE-DMD, that’s designed to treat the neurodegenerative disease by altering the patient’s own genetic code. Precision Biosciences, the U.S. company developing PBGENE-DMD, announced that dosing had begun in the…